All In Biotech

Drug Trial Radar · NCT04923893

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 743 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

743

Actual

Start

Aug 19, 2021

Primary completion

Feb 14, 2029

Study completion Sep 22, 2036

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jun 11, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) versus VRd induction followed by Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple myeloma participants for whom ASCT is not planned as initial therapy in terms of Progression Free Survival (PFS).

Conditions

  • Multiple Myeloma

Interventions

  • BortezomibDrug

    Bortezomib will be administered SC.

  • DexamethasoneDrug

    Dexamethasone will be administered orally.

  • LenalidomideDrug

    Lenalidomide will be administered orally.

  • Cilta-celDrug

    Cilta-cel infusion will be administered.

  • CyclophosphamideDrug

    Cyclophosphamide will be administered intravenously.

  • FludarabineDrug

    Fludarabine will be administered intravenously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: Up to 4 years and 5 months

Locations

136 sites in 26 countries. Site status is shown where the registry gives one.

  • UCSF

    San Francisco, California

  • Yale Cancer Center

    New Haven, Connecticut

  • University of Miami Health System

    Miami, Florida

  • AdventHealth Cancer Institute

    Orlando, Florida

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • University of Kentucky

    Lexington, Kentucky

  • Norton Cancer Institute

    Louisville, Kentucky

  • University Of Maryland Medical Center

    Baltimore, Maryland

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan

  • Henry Ford Cancer Institute

    Detroit, Michigan

  • Columbia University Medical Center

    New York, New York

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • New York Presbyterian-Weill Cornell Medical College

    New York, New York

  • Levine Cancer Institute

    Charlotte, North Carolina

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • University of Virginia

    Charlottesville, Virginia

  • Medical College Of Wisconsin

    Milwaukee, Wisconsin

  • Hospital Aleman

    Buenos Aires, Argentina

  • Hospital Italiano de Buenos Aires

    Buenos Aires, Argentina

  • Hospital Privado Universitario De Cordoba

    Córdoba, Argentina

  • Royal Prince Alfred Hospital

    Camperdown, Australia

  • St Vincents Hospital Melbourne

    Fitzroy, Australia

  • Austin Health

    Heidelberg, Australia

  • Royal Brisbane and Womens Hospital

    Herston, Australia

  • Alfred Health

    Melbourne, Australia

  • Peter MacCallum Cancer Centre

    Melbourne, Australia

  • Fiona Stanley Hospital

    Murdoch, Australia

  • Calvary Mater Newcastle Hospital

    Waratah, Australia

  • Western Sydney Local Health District

    Westmead, Australia

  • Medizinische Universitat Graz, LKH-Univ.Klinikum Graz, Klinische Abteilung für Hämatologie

    Graz, Austria

  • Krankenhaus der Elisabethinen Linz

    Linz, Austria

  • LKH - Universitätsklinikum der PMU Salzburg

    Salzburg, Austria

  • Medical University of Vienna Universitatsklinik fur Innere Medizin I

    Vienna, Austria

  • Universitair Ziekenhuis - Antwerpen

    Antwerp, Belgium

  • AZ St.-Jan Brugge-Oostende AV

    Bruges, Belgium

  • UZ Gent

    Ghent, Belgium

  • UZ Leuven

    Leuven, Belgium

  • Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman

    Liège, Belgium

Showing 40 of 136 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.